EHT/AGN 0001 is a Phase II-ready, orally bio-available little molecule in clinical development for neuropathic discomfort. This agreement between Allergan and Bristol-Myers Squibb also encompasses EHT/AGN 0002 and associated back-up compounds.D., President of ExonHit Therapeutics’ Management Board. Whitcup, M.D., Executive Vice President, Analysis & Advancement and Chief Scientific Officer at Allergan. ExonHit might also receive potential EHT/AGN 0001 related advancement – and regulatory-based milestone obligations exceeding USD $32 million and royalties on future world-wide sales.Sears that health care professionals dose by pounds, not by age. Kids the same age USUALLY DO NOT weigh the same, so in retrospect all Children’s AccuDial medicines provide dosing directions predicated on your child’s weight.’ AccuDial’s family of eight pediatric, OTC medications was approved by Wellness Canada last year. Children’s AccuDial is the only medication that delivers weight-specific dosing using a rotating label.